Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 29;6(7):FSO587.
doi: 10.2144/fsoa-2020-0018.

Investigation of Copaifera genus as a new source of antimycobaterial agents

Jéssica Aparecida Alves  1 , Fariza Abrão  1 , Thaís da Silva Moraes  1 , Jaqueline Lopes Damasceno  1 , Marcos Fernando Dos Santos Moraes  2 , Rodrigo Cassio Sola Veneziani  2 , Sérgio Ricardo Ambrósio  2 , Jairo Kenupp Bastos  3 , Mayker Lázaro Dantas Miranda  4 , Carlos Henrique Gomes Martins  1   5
Affiliations

Investigation of Copaifera genus as a new source of antimycobaterial agents

Jéssica Aparecida Alves et al. Future Sci OA. .

Abstract

Aim: This paper reports on the antimycobacterial activity of the oleoresins and extracts obtained from Copaifera spp.

Materials & methods: The minimum inhibitory concentration (MIC) and fractional inhibitory concentration index techniques helped to evaluate the effect of these oleoresins and extracts against six strains of mycobacteria that cause tuberculosis.

Results & conclusion: Among the assayed oleoresins and plant extracts, the Copaifera langsdorffii, Copaifera duckei, Copaifera reticulata and Copaifera trapezifolia oleoresins provided the lowest MIC values against some of the tested strains. The combination of Copaifera spp. samples with isoniazid did not evidence any synergistic action. Some Copaifera spp. oleoresins may represent a future source for the discovery of new antimycobacterial drugs due to their low MIC values.

Keywords: Copaifera spp.; Mycobacterium tuberculosis; antimicrobial activity; crude extracts; oleoresins.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure This work was kindly supported by the São Paulo Research Foundation – FAPESP, Processes number # 2011/13630-7 and # 2012/25237-0 and Coordination for the Improvement of Higher Level Personnel (CAPES) and National Council for Scientific and Technological Development (CNPq). The authors have no affiliations or financial involvement with any organization or entity with a financial interest in this work or financial conflict. No writing assistance was utilized in the production of this manuscript.

References

    1. Lin HC, Perng CL, Lai YW. et al. Molecular screening of multidrug-resistance tuberculosis by a designated public health laboratory in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis. 36(12), 2431–2439 (2017). - PMC - PubMed
    1. Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration 91(5), 386–402 (2016). - PubMed
    1. Zumla A, Raviglione M, Hafner R. et al. Tuberculosis. N. Engl. J. Med. 368(8), 745–755 (2013). - PubMed
    1. Hawn TR, Day TA, Scriba TJ. et al. Tuberculosis vaccines and prevention of infection. Microbiol. Mol. Biol. Rev. 78, 650–671 (2014). - PMC - PubMed
    1. WHO. Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis. WHO, Geneva, Switzerland: (2019).

LinkOut - more resources